1. From the The Hull Family Cardiac Fibrillation Management Laboratory (S.K.H., K.M., A.P.-S., S.M., P.F.H.L., M.A.A., J.A., M.K., A.C.T.H., V.C., K.N.) and Toronto Health Economics and Technology Assessment Collaborative (N.M.), Toronto General Hospital, University Health Network, Ontario, Canada; St. Michael's Hospital, Toronto, Ontario, Canada (P.D.); and Abbott Laboratories, St. Paul, MN (D.C.D.).